Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54

Fly Intel: After Hours Movers

HIGHER: NewLink (NLNK) up 17.8% after FDA accepted its partnered BLA for ebola vaccine... CDW Corp (CDW) up 5.6% after entering S&P500 index... Tellurian (TELL) up 2.0% after being initiated with Outperform at Evercore... NextDecade (NEXT) up 1.9% after being initiated with Outperform at Evercore. DOWN AFTER EARNINGS: FedEx (FDX) down 9.6%, XPO Logistics (XPO) down 3.4% in symbathy... Chewy (CHWY) down 2.8%... Adobe (ADBE) down 2.6%. ALSO LOWER: Adesto Technologies (IOTS) down 8.5% after convertible debt offering... PTC Therapeutics (PTCT) down 7.7% after equity offering... Translate Bio (TBIO) down 7.6%... Acadia Pharma (ACAD) down 2.6% after equity offering. Movers as of 18:30ET.

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

NLNK NewLink Genetics
$1.90

-0.03 (-1.55%)

01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
NewLink Genetics downgraded to Underperform from Neutral at BofA/Merrill
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
NewLink Genetics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded NewLink Genetics to Underperform from Neutral and lowered its price target to $1 from $5. Analyst Ying Huang said he lacks conviction for indoximod after epacadostat efficacy in Phase 3 study was underwhelming.
CDW CDW
$113.91

0.94 (0.83%)

08/05/19
08/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Williams (WMB) downgraded to Market Perform from Outperform at Bernstein with analyst Jean Ann Salisbury saying as delays in LNG starts and surprising growth from the SW Marcellus/Utica and Haynesville she pulled her bearish gas thesis of half-cycle breakeven gas forward. 2. GlycoMimetics (GLYC) downgraded to Hold from Buy at Jefferies and SunTrust while being downgraded to Neutral from Overweight at Piper Jaffray. 3. Prudential (PRU) downgraded to Neutral from Buy at Citi with analyst Suneet Kamath saying he sees "muted" earnings growth for Prudential over at least the next year or so. 4. Mercer (MERC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Paul Quinn citing its Q2 earnings miss. 5. CDW (CDW) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/19
FBCO
08/01/19
NO CHANGE
Target $132
FBCO
Outperform
CDW price target raised to $132 from $118 at Credit Suisse
Credit Suisse analyst Matthew Cabral raised his price target for CDW to $132 from $118 after the company delivered "another strong set of results" in Q2. The analyst reiterates an Outperform rating on the shares.
08/05/19
JPMS
08/05/19
DOWNGRADE
Target $116
JPMS
Underweight
CDW downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded CDW Corp. to Underweight from Neutral with an unchanged price target of $116. The analyst cites valuation and "elevated near-term risk" associated with the Win10 upgrade cycle. CDW has 40% exposure to the corporate end-market where Coster sees a potential hiatus in IT hardware spending. He says his Underweight rating is "somewhat short-term focused" as he does not view CDW as a short.
07/30/19
BOFA
07/30/19
INITIATION
Target $140
BOFA
Buy
CDW initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Param Singh initiated CDW with a Buy rating and $140 price target. The analyst cites the company's continued execution relative to its financial targets with "strong" free cash flows and capital returns while meeting or beating consensus every quarter since going public in 2013. Singh believes CDW can generate upside to Street consensus with its from continuous outperformance and market share gains as well as "significantly" boost dividends.
TELL Tellurian
$8.33

-0.1 (-1.19%)

09/17/19
EVER
09/17/19
INITIATION
Target $14
EVER
Outperform
Tellurian initiated with an Outperform at Evercore ISI
Evercore ISI started Tellurian with an Outperform rating and $14 price target.
08/23/19
BOFA
08/23/19
DOWNGRADE
Target $9.5
BOFA
Neutral
Tellurian downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith downgraded Tellurian to Neutral from Buy and raised its price target to $9.50 from $9 citing recent share strength and notes modest cash burn near-term.
07/16/19
STFL
07/16/19
DOWNGRADE
STFL
Hold
Tellurian downgraded to Hold from Buy at Stifel
Stifel analyst Benjamin Nolan downgraded Tellurian to Hold from Buy and lowered his price target on shares to $9 from $16. The analyst said he sees growth in LNG production limiting gas price upside, and pointed out that lower gas prices longer term would "have a negative impact on Tellurian's marketing margins and consequently their discounted cash flows." Nolan concluded that with a "dampened view on LNG prices," he no longer believes the shares offer "a risk/reward worth taking."
07/18/19
STFL
07/18/19
NO CHANGE
Target $9
STFL
Hold
Tellurian higher after Stifel issues 'Mea Culpa' on share count calculation
Shares of Tellurian (TELL) are higher in afternoon trading following a note issued before the open by a Stifel analyst who corrected a prior mistake he found in his calculations when having downgraded the stock earlier this week. In a note titled "Mea Culpa on TELL Share Count," analyst Benjamin Nolan acknowledged that in his downgrade published on July 16 he had an error in his calculation of the proposed private equity component of Tellurian's capital structure. After correcting his prior mistake, Nolan said there would be more potential upside should the company get to Final Investment Decision, or FID, on phase 1 of the Driftwood LNG project. He raised his "fully baked" discounted cash flow value estimate to $36 per share from $26 per share given the correction, though Nolan maintains a Hold rating and $9 price target on Tellurian shares. The stock is up 31c, or 4.7%, to $6.98 in afternoon trading.
NEXT NextDecade
$6.30

-0.1 (-1.56%)

02/08/19
SCOT
02/08/19
INITIATION
SCOT
Sector Perform
NextDecade initiated with a Sector Perform at Scotiabank
Scotiabank analyst Alonso Guerra-Garcia initiated NextDecade with a Sector Perform and $4.50 price target.
04/05/19
WOLF
04/05/19
UPGRADE
WOLF
Peer Perform
NextDecade upgraded to Peer Perform from Underperform at Wolfe Research
Wolfe Research upgraded NextDecade to Peer Perform form Underperform citing the SPA signed with Royal Dutch Shell (RDS.A). The firm's analyst believes views this as a milestone development as it represents NextDecade's Rio Grande facility's first offtake contract.
05/13/19
GABE
05/13/19
INITIATION
GABE
Buy
NextDecade initiated with a Buy at Gabelli
Gabelli analyst Matthew Trusz started NextDecade with a Buy rating and $19 private market value estimate. The analyst believes the company is positioned to out-earn other U.S. projects in a medium or high oil price environment.
09/17/19
EVER
09/17/19
INITIATION
Target $11
EVER
Outperform
NextDecade initiated with an Outperform at Evercore ISI
Evercore ISI started NextDecade with an Outperform rating and $11 price target.
FDX FedEx
$173.53

-0.14 (-0.08%)

08/08/19
MSCO
08/08/19
NO CHANGE
MSCO
Equal Weight
Financial impact of Amazon break-up limited for FedEx, says Morgan Stanley
After various media sources indicated yesterday that FedEx (FDX) and Amazon (AMZN) each confirmed that they will not renew their ground-delivery contract, Morgan Stanley analyst Ravi Shanker said he thinks the financial impact to FedEx should be limited, but "the symbolic impact for Parcels is significant." One of the two largest e-commerce parcel delivery companies in the U.S. is no longer doing any business with the dominant e-commerce player, which "would have been unthinkable 5-7 years ago," wrote Shanker, who questions if UPS (UPS) cannot afford to similarly break up with Amazon given their outsized exposure to them as a customer. He also questions when Amazon's contract with UPS is up for renewal and what they will do when that happens given Amazon's recent history of suddenly pulling or not renewing deals, such as with FedEx and XPO Logistics (XPO). Shanker has an Equal Weight rating on FedEx and an Underweight rating on UPS.
08/22/19
SBSH
08/22/19
NO CHANGE
SBSH
Buy
FedEx estimates lowered ahead of Q1 report at Citi
Citi analyst Christian Wetherbee said it appears that incremental headwinds have emerged for FedEx three months into the fiscal year, leading him to lower his estimates ahead of the company's report on September 17. While he expects the shares to be range-bound in the near-term as cuts to consensus forecasts are digested, he also believes much of this risk is factored into FedEx shares already and keeps a Buy rating on the stock.
07/10/19
07/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinduoduo (PDD) initiated with an Underweight at JPMorgan. 2. Zillow (ZG) and Redfin (RDFN) were initiated with a Buy at SunTrust. 3. Wabtec (WAB) was initiated with a Neutral at Citi and Goldman Sachs. 4. FedEx (FDX) was initiated with a Conviction Buy at Goldman Sachs while UPS (UPS) was initiated with a Buy. 5. A.O. Smith (AOS) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/19
DBAB
09/17/19
DOWNGRADE
DBAB
Hold
FedEx downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Amit Mehrotra downgraded FedEx to Hold from Buy saying he's "lost confidence" following tonight's Q1 results.
XPO XPO Logistics
$73.83

-0.76 (-1.02%)

08/06/19
RHCO
08/06/19
NO CHANGE
Target $80
RHCO
Buy
XPO Logistics price target raised to $80 from $75 at SunTrust
SunTrust analyst Stephanie Benjamin raised her price target on XPO Logistics to $80 after its Q2 earnings beat, citing the 5.2% price increase in contract renewals and noting that the recent quarter marks "just the beginning" of pricing and margin improvement in LTL trucking. The analyst keeps her Buy rating on the stock, forecasting accelerating EBITDA growth in the back half of 2019 as the company benefits from ramping of contract wins in the ContractLogistics segment and new innovations in LTL that lower costs.
08/05/19
JEFF
08/05/19
NO CHANGE
Target $98
JEFF
Buy
XPO Logistics price target raised to $98 from $92 at Jefferies
Jefferies analyst David Kerstens raised his price target for XPO Logistics to $98 from $92 saying the company's earnings momentum improved in Q2. Meanwhile, XPO's current valuation implies a 45% discount to logistics peers, and a 10% discount to U.S. trucking, Kerstens tells investors in a research note titled "Getting Back on Track with Earnings Momentum Improving." The analyst keeps a Buy rating on the shares.
08/05/19
FBCO
08/05/19
NO CHANGE
Target $81
FBCO
Outperform
XPO Logistics price target raised to $81 from $73 at Credit Suisse
Credit Suisse analyst Allison Landry raised her price target for XPO Logistics to $81 from $73 following "decent" results, particularly considering the less than cooperative backdrop. While the analyst notes that some investors are skeptical of the EBITDA and free cash flow raise, she points toward a number of positives such as strong LTL pricing/trajectory of margin improvement; a recent material customer win in the U.K.; a full pipeline of new biz wins; and a clearly defined set of revenue and cost initiatives that should support "solid profit growth" for the next few years. Landry reiterates an Outperform rating on the shares.
CHWY Chewy
$30.20

-0.2 (-0.66%)

07/09/19
RAJA
07/09/19
INITIATION
RAJA
Market Perform
Chewy shares fairly valued, risk-reward balanced, says Raymond James
Raymond James analyst Aaron Kessler initiated Chewy with a Market Perform rating. In a research note to investors, Kessler says he believes shares have several positive fundamental attributes, including a large pet care market that is shifting online, "predictable" customer economics, the expectation for about 20% long-term growth and 5%-10% long-term EBITDA margin expansion. At the same time, Kessler says he believes shares are currently fairly valued and that risk-reward is more balanced at current levels.
07/09/19
WBLR
07/09/19
INITIATION
WBLR
Outperform
Chewy initiated with an Outperform at William Blair
William Blair analyst Dylan Carden initiated coverage of Chewy with an Outperform rating. At $34, the shares trade at 2.3 times estimated 2020 sales, a relative discount to other online retail platforms and subscription models, which trade closer to four times 2020 sales, Carden tells investors in a research note. The analyst sees room for multiple expansion but believes the "greatest value" for shareholders stems from the company's opportunity to continue to capture disproportionate market share of a "healthy and fast-growing" industry.
07/09/19
07/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chewy (CHWY) was initiated with an Outperform at William Blair and Wells Fargo, an Overweight at JPMorgan, a Buy at BofA/Merrill and UBS, an Equal Weight at Morgan Stanley and Barclays, a Market Perform at Raymond James, a Sector Perform at RBC Capital, a Hold at Jefferies, and a Neutral at Nomura Instinet. 2. Intellia Therapeutics (NTLA) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Perform at Oppenheimer. 4. AAR Corp. (AIR) initiated with a Buy at Stifel. 5. Vista Outdoor (VSTO) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/15/19
CHLM
07/15/19
NO CHANGE
CHLM
Sell
PetMed CEO amendment hints at exploration of alternatives, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich noted that PetMed Express (PETS) filed an 8K after the close on Friday to disclose that it amended CEO Mendo Akdag's employment agreement to add the language "for Good Reason" to the "Change in Control" section. He reads this change as a hint that an exploration of strategic alternatives could be upcoming, though he doesn't think there is anything imminent in the works. The analyst, who suspects there is further downside to Street estimates for PetMed given increased competition from Chewy (CHWY), Walmart (WMT), Petco and other online retailers, keeps a Sell rating on PetMed shares.
ADBE Adobe
$284.59

1.54 (0.54%)

06/19/19
RBCM
06/19/19
NO CHANGE
Target $295
RBCM
Outperform
Adobe price target raised to $295 from $290 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on Adobe to $295 and kept his Outperform rating after its better than expected Q2 results. The analyst also notes that while the company's Q3 outlook was below consensus, its maintained FY19 guidance implies a "big Q4", which he sees as "very much achievable". The analyst contends that Adobe is just beginning to "flex pricing" for its Creative base, which has had static rates )since the launch of the service in FY12. Hedberg further believes that the company's Creative Suite conversion opportunity is "under-appreciated" with as many as 6M users still in the install base, while noting that its operating expenses could also come in lower.
06/20/19
ARGS
06/20/19
NO CHANGE
Target $320
ARGS
Buy
Adobe positioned at 'center of exploding market' for digital video, says Argus
Argus analyst Joseph Bonner kept his Buy rating and $320 price target on Adobe after its "strong" Q2 results, also maintaining his FY19 and FY20 EPS forecasts of $7.85 and $9.77. The analyst believes that the company is well positioned at the "center of the exploding market for digital video content" with a unique asset collection in its Creative Cloud digital content portfolio. Bonner further sees Adobe continuing to "accelerate organic product refreshes and new rollouts" as well as partnering with industry leaders to drive further growth.
09/13/19
RBCM
09/13/19
INITIATION
Target $320
RBCM
Outperform
Adobe assumed with an Outperform at RBC Capital
RBC Capital analyst Alex Zukin assumed coverage of Adobe with an Outperform rating and a raised price target of $320 from $295 prior ahead of its earnings next week. The analyst notes that his checks point to an "in-line or better quarter", with strong pipeline going into Q4. Zukin also sees Adobe as a "best in class asset" that is positioned to outperform over multiple market cycles, adding that its Creative Cloud business offers high pricing power and potential for secular growth predicated with "long-term user growth".
07/17/19
UBSW
07/17/19
NO CHANGE
Target $330
UBSW
Buy
UBS believes Adobe can sustain profit growth
UBS analyst Jennifer Lowe kept her Buy rating and $330 price target on Adobe, saying that in spite of its revenue stream shifting to lower-margin Digital Experience channel from the higher margin Digital Media segment, she believes the company can sustain an operating profit and earnings growth of 20% or more. The analyst contends that the company's profit growth should support the current enterprise value to expected 2020 earnings multiple of 31-times and expects Adobe shares to continue moving higher.
IOTS Adesto Technologies
$10.63

-0.66 (-5.85%)

08/12/19
NORL
08/12/19
DOWNGRADE
NORL
Market Perform
Adesto downgraded to Market Perform at Northland after $10 target achieved
As previously reported, Northland analyst Gus Richard downgraded Adesto Technologies (IOTS) to Market Perform from Outperform after the stock reached his prior price target of $10. The company has $34M of high interest debt and needs $10M to pay an earnout by year end, but Richard thinks the company is holding off on an offering until it reports a "strong" third quarter that will be boosted by an airpod win at Apple (AAPL), he tells investors.
08/12/19
08/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NetEase (NTES) downgraded to Neutral from Buy at Goldman Sachs with analyst Bill Liu citing the company's Q2 revenues miss, mainly on soft online games growth. 2. Occidental Petroleum (OXY) downgraded to In Line from Outperform at Evercore ISI with analyst Doug Terreson saying the company's "pledge" for greater capital discipline and enhanced corporate governance "proved fleeting" with the significant decline in return on capital employed due to the Anadarko acquisition. 3. Adesto Technologies (IOTS) downgraded to Market Perform from Outperform at Northland with analyst Gus Richard saying the company has $34M of high interest debt and needs $10M to pay an earnout by year end, but he thinks the company is holding off on an offering until it reports a "strong" third quarter that will be boosted by an airpod win at Apple (AAPL). 4. Bluebird Bio (BLUE) downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. 5. Cemex (CX) downgraded to Market Perform from Outperform at BBVA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/19
NORL
08/12/19
DOWNGRADE
NORL
Market Perform
Adesto Technologies downgraded to Market Perform from Outperform at Northland
09/17/19
LOOP
09/17/19
INITIATION
Target $13
LOOP
Buy
Adesto Technologies initiated with a Buy at Loop Capital
Loop Capital started Adesto Technologies with a Buy rating and $13 price target.
PTCT PTC Therapeutics
$43.26

0.27 (0.63%)

07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
09/17/19
SBSH
09/17/19
NO CHANGE
SBSH
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list
Citi analyst Joel Beatty removed The Medicines Co. (MDCO) and Minerva (NERV) from his top five Buy-rated stocks in SMid cap Biotech. These stocks are up 34% and 28%, respectively, since the analyst established them as among his top five Buy-rated stocks in July. Beatty replaced The Medicines Co. and Minerva with Amarin (AMRN) and Sarepta Therapeutics (SRPT). His top five buys are now Amarin, Eloxx Pharmaceuticals (ELOX), NGM Biopharmaceuticals (NGM), PTC Therapeutics (PTCT) and Sarepta. He wants to own Amarin into the November FDA panelmeeting, believing it will be "innocuous" and lead to a risk reduction label for Vascepa. On Sarepta, Beatty thinks the recent share pullback is overblown, and he reiterates his thesis that "although there will likely be some minor bumps on the road," the company will ultimately win the Image result for Duchenne muscular dystrophy gene therapy race
05/28/19
CANT
05/28/19
NO CHANGE
Target $61
CANT
Overweight
PTC Therapeutics remains a top small-mid-cap franchise pick at Cantor Fitzgerald
After traveling with management, Cantor Fitzgerald analyst Alethia Young says PTC Therapeutics remains a top small-mid-cap franchise pick. The company has "many realizable shots on goal" that remain unappreciated at current share levels, Young tells investors in a research note. She thinks investors assign little credit to PTC's AADC deficiency opportunity in gene therapy. Young models peak sales of $400M and a 20% probability of success. The analyst reiterates an Overweight rating on PTC Therapeutics with a $61 price target.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
TBIO Translate Bio
$11.01

0.405 (3.82%)

07/22/19
JEFF
07/22/19
INITIATION
Target $20
JEFF
Buy
Translate Bio initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started Translate Bio with a Buy rating and $20 price target. The company's first human Phase 1/2 efficacy data in 2020, if positive, will provide "meaningful upside" in the shares, Yang tells investors in a research note.
06/18/19
ROTH
06/18/19
INITIATION
Target $25
ROTH
Buy
Translate Bio initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler started coverage of Translate Bio (TBIO) with a Buy rating and a $25 price target. The analyst believes that with its engineered mRNA and LPN delivery vehicles, Translate Bio's MRT platform has the advantages of enhanced stability, lower immunogenicity, tissue-specific delivery, and potentially scalable manufacturing. Butler also sees Sanofi (SNY) partnership providing resources and broadening the pipeline.
06/18/19
06/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ViewRay (VRAY) initiated with an Overweight at Piper Jaffray. 2. Premier (PINC) initiated with a Neutral at Guggenheim. 3. Stealth Biotherapeutics (MITO) initiated with a Buy at H.C. Wainwright. 4. Twilio (TWLO) initiated with a Buy at Needham. 5. Translate Bio (TBIO) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $24
PIPR
Overweight
Translate clinical hold has no read-through to Moderna, says Piper Jaffray
Moderna's (MRNA) messenger RNA competitor Translate Bio (TBIO) announced this morning that the FDA placed a clinical hold on its Investigational New Drug Application for MRT5201 to treat ornithine transcarbamylase deficiency, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Translate Bio also had a prior clinical IND hold on MRT5005 for cystic fibrosis due to manufacturing issues, adds the analyst. Tenthoff does not see read-through to Moderna's mRNA platform and pipeline from the news. The FDA accepted the company's IND for mRNA-3704 to treat orphan disease methylmalonic acidemia, and the Phase I/II study will begin soon, says the analyst. He reiterates an Overweight rating on Moderna with a $24 price target. The stock in midday trading is down 3% to $16.15.
ACAD Acadia
$42.60

-1.45 (-3.29%)

09/13/19
LEER
09/13/19
UPGRADE
Target $50
LEER
Outperform
SVB Leerink 'significantly more positive' on DRP, upgrades Acadia to Outperform
As previously reported, SVB Leerink analyst Marc Goodman upgraded Acadia to Outperform from Market Perform and raised his price target on the shares to $50 from $21 based on the recently announced results from the Phase 3 HARMONY study in Dementia Related Psychosis, or DRP. Following the announcement of the trial results, he conducted calls with Key Opinion Leaders specialized in treating both Parkinson's and Alzheimer's/Dementia patients, which left him "significantly more positive" on the DRP opportunity, Goodman tells investors. The positive physician feedback drove him to increase his peak sales estimate for the DRP indication to about $2B from the $500M-$750M range, Goodman noted.
09/13/19
LEER
09/13/19
UPGRADE
Target $50
LEER
Outperform
Acadia upgraded to Outperform from Market Perform at SVB Leerink
SVB Leerink analyst Marc Goodman upgraded Acadia to Outperform from Market Perform and raised his price target on the shares to $50 from $21.
09/10/19
ADAM
09/10/19
UPGRADE
Target $50
ADAM
Buy
Acadia upgraded to Buy at Canaccord
As reported previously, Canaccord analyst Sumant Kulkarni upgraded Arcadia after the company announced it stopped it pivotal Phase 3 HARMONY trial in dementia-related psychosis after primavanserin hit its primary endpoint. . The analyst believes this puts the company back on the short list of company/assets that present scarcity and value for strategic interests in the neuro space. Kulkarni raised his price target to $50 from $29 on Arcadia shares.
09/13/19
09/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kemet (KEM) upgraded to Buy from Hold at Stifel with analyst Matthew Sheerin stating that while the company is facing headwinds similar to competitors amid weakening demand and an inventory correction, its fundamentals have held up significantly better than comps due primarily to its product portfolio. 2. Advance Auto Parts (AAP) upgraded to Buy from Neutral at Citi with analyst Gregory Badishkanian saying same-store sales momentum, assortment optimization and omni-channel initiatives should drive sales growth. 3. M.D.C. Holdings (MDC) upgraded to Strong Buy from Outperform at Raymond James with analyst Buck Horne noting the company's released preliminary Q3 net order activity through July and August is tracking "dramatically ahead" of his prior expectations. 4. Etsy (ETSY) upgraded to Outperform from Neutral at Wedbush with analyst Ygal Arounian telling investors he now sees a critical mass of new initiatives, highlighted by Etsy Ads and free shipping, that can drive stronger GMS growth and margin expansion over time. 5. Acadia (ACAD) upgraded to Outperform from Market Perform at SVB Leerink with analyst Marc Goodman citing the recently announced results from the Phase 3 HARMONY study in Dementia Related Psychosis. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

10:35
10/18/19
10/18
10:35
10/18/19
10:35
General news
Treasury Action: Treasury yields are a little richer in a bull steepening trade »

Treasury Action: Treasury…

INCY

Incyte

$79.20

1.8 (2.33%)

10:32
10/18/19
10/18
10:32
10/18/19
10:32
Conference/Events
JMP Securities biotech analyst to hold an analyst/industry conference call »

Biotechnology Benjamin,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

M

Macy's

$15.03

-0.74 (-4.69%)

, LB

L Brands

$16.61

-1.49 (-8.23%)

10:32
10/18/19
10/18
10:32
10/18/19
10:32
On The Fly
Softline retailers under pressure as Credit Suisse sees 'tougher road ahead' »

Shares of retailers…

M

Macy's

$15.03

-0.74 (-4.69%)

LB

L Brands

$16.61

-1.49 (-8.23%)

GPSN

GPS Industries Inc

$0.00

(0.00%)

JWN

Nordstrom

$34.40

-0.66 (-1.88%)

KSS

Kohl's

$50.95

-0.1 (-0.20%)

JCP

J.C. Penney

$1.01

-0.005 (-0.50%)

LEVI

Levi Strauss

$17.13

0.08 (0.47%)

VFC

VF Corp.

$91.76

0.15 (0.16%)

ROST

Ross Stores

$113.77

0.76 (0.67%)

BURL

Burlington Stores

$202.12

-0.29 (-0.14%)

NKE

Nike

$95.24

-0.3 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 25

    Oct

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

XLF

Financial Select Sector

$28.05

(0.00%)

10:30
10/18/19
10/18
10:30
10/18/19
10:30
Options
Long-dated put buyer in Financial ETF appears to add to large position »

Long-dated put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$144.27

-1.9 (-1.30%)

10:25
10/18/19
10/18
10:25
10/18/19
10:25
Options
Salesforce call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 16

    Dec

10:25
10/18/19
10/18
10:25
10/18/19
10:25
General news
Fed's George said her outlook does not call for another rate cut »

Fed's George said…

10:25
10/18/19
10/18
10:25
10/18/19
10:25
Conference/Events
Federal Reserve Bank of Minneapolis president participates in a summit »

Minneapolis Federal…

SCHW

Charles Schwab

$39.75

0.29 (0.73%)

10:25
10/18/19
10/18
10:25
10/18/19
10:25
Conference/Events
Charles Schwab to host business news update conference call »

President & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 27

    Oct

CG

Carlyle Group

$27.06

-0.07 (-0.26%)

10:22
10/18/19
10/18
10:22
10/18/19
10:22
Periodicals
Carlyle in talks to buy Goya in deal valuing food company at $3.5B, NY Post says »

Goya Foods is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 31

    Oct

STT

State Street

$61.41

1.7 (2.85%)

10:22
10/18/19
10/18
10:22
10/18/19
10:22
Hot Stocks
State Street sees servicing fees 'flattish' in Q4, management fees up 1%-2% »

Sees markets business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

10:20
10/18/19
10/18
10:20
10/18/19
10:20
General news
FX Action: The dollar »

FX Action: The dollar…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/18/19
10/18
10:17
10/18/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/18/19
10/18
10:16
10/18/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
10/18/19
10/18
10:15
10/18/19
10:15
Conference/Events
JPMorgan autos/auto parts analyst to hold an analyst/industry conference call »

Autos & Auto Parts…

10:15
10/18/19
10/18
10:15
10/18/19
10:15
General news
U.S. leading economic index dipped -0.1% to 111.9 in September »

U.S. leading economic…

10:15
10/18/19
10/18
10:15
10/18/19
10:15
General news
Breaking General news story  »

Minneapolis Federal…

NIO

NIO Inc.

$1.48

0.01 (0.68%)

10:10
10/18/19
10/18
10:10
10/18/19
10:10
Options
Nov 1.5 put seller in NIO cashes out 140% winner »

Nov 1.5 put seller in NIO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$76.60

0.75 (0.99%)

, PINS

Pinterest

$25.86

-0.14 (-0.54%)

10:06
10/18/19
10/18
10:06
10/18/19
10:06
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

IRET

Investors Real Estate

$76.60

0.75 (0.99%)

PINS

Pinterest

$25.86

-0.14 (-0.54%)

SNAP

Snap

$14.00

0.22 (1.60%)

IDN

Intellicheck

$5.00

(0.00%)

WBT

Welbilt

$17.97

(0.00%)

DAVA

Endava

$40.06

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 31

    Oct

  • 05

    Nov

  • 07

    Nov

  • 11

    Nov

  • 12

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 16

    Oct

GIL

Gildan Activewear

$25.88

-9.495 (-26.84%)

, CAT

Caterpillar

$131.37

1.36 (1.05%)

10:06
10/18/19
10/18
10:06
10/18/19
10:06
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GIL

Gildan Activewear

$25.88

-9.495 (-26.84%)

CAT

Caterpillar

$131.37

1.36 (1.05%)

CRL

Charles River

$135.10

-0.97 (-0.71%)

M

Macy's

$14.98

-0.79 (-5.01%)

LB

L Brands

$16.56

-1.54 (-8.51%)

GPS

Gap

$16.53

-1.05 (-5.97%)

WM

Waste Management

$115.34

-0.97 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 31

    Oct

  • 04

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

MO

Altria Group

$44.40

0.14 (0.32%)

, SNAP

Snap

$13.99

0.21 (1.52%)

10:06
10/18/19
10/18
10:06
10/18/19
10:06
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

MO

Altria Group

$44.40

0.14 (0.32%)

SNAP

Snap

$13.99

0.21 (1.52%)

CMG

Chipotle

$846.04

17.95 (2.17%)

RSG

Republic Services

$87.30

1.15 (1.33%)

WCN

Waste Connections

$92.97

0.7 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 12

    Nov

STT

State Street

$60.83

1.12 (1.88%)

10:05
10/18/19
10/18
10:05
10/18/19
10:05
Hot Stocks
State Street says reigniting servicing fee revenue growth remains a top priority »

Comments taken from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

10:02
10/18/19
10/18
10:02
10/18/19
10:02
General news
Leading Indicators data reported »

September Leading…

SXT

Sensient

$60.60

-5.97 (-8.97%)

10:00
10/18/19
10/18
10:00
10/18/19
10:00
Hot Stocks
Sensient falls -8.8% »

Sensient is down -8.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

NNA

Navios Acquisition

$8.58

-1.78 (-17.18%)

10:00
10/18/19
10/18
10:00
10/18/19
10:00
Hot Stocks
Navios Acquisition falls -17.6% »

Navios Acquisition is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIL

Gildan Activewear

$26.26

-9.12 (-25.78%)

10:00
10/18/19
10/18
10:00
10/18/19
10:00
Hot Stocks
Gildan Activewear falls -25.8% »

Gildan Activewear is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.